Discovery of new development paths for multiple clinical drug candidates to be pursued.
Gene Logic will seek alternative development paths for multiple Eli Lilly drug candidates under a drug repositioning and development agreement between the two firms. All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.

The agreement provides for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lilly’s contribution as the originator of the compound. The agreement also provides Gene Logic the option to receive an exclusive license to any drug candidate that Lilly chooses not to pursue, in which case Lilly would receive success-based milestone and royalty payments.

Gene Logic’s Drug Repositioning Program seeks to find alternative development paths for drug candidates with good safety records that have been de-prioritized or discontinued in clinical trials.

Previous articleDavid Weiner, Ph.D.
Next articleNovel Two-Gene Ratio Found to Be a Prognostic Indicator of Breast Cancer Recurrence Risk